Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (F:RIG2) — Market Cap & Net Worth

$6.56 Billion USD  · €5.61 Billion EUR  · Rank #3042

Market Cap & Net Worth: Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2)

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (F:RIG2) has a market capitalization of $6.56 Billion (€5.61 Billion) as of June 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #3042 globally and #590 in its home market, demonstrating a 0.06% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's stock price €34.38 by its total outstanding shares 182387869 (182.39 Million). Review Richter Gedeon Vegyészeti Gyár Nyilvános balance sheet liabilities to assess the company's total debt and financial obligations.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Market Cap History: 2015 to 2026

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market capitalization history from 2015 to 2026. Data shows growth from $3.70 Billion to $7.33 Billion (8.11% CAGR).

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.01x

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market cap is 0.01 times its annual revenue

Industry average: 0.53x Lower than industry average

Latest Price to Earnings (P/E) Ratio

0.02x

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market cap is 0.02 times its annual earnings

Industry average: 0.02x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $4.15 Billion $389.69 Billion $66.20 Billion 0.01x 0.06x
2017 $4.60 Billion $444.36 Billion $8.88 Billion 0.01x 0.52x
2018 $3.56 Billion $445.48 Billion $35.35 Billion 0.01x 0.10x
2019 $4.05 Billion $507.79 Billion $47.13 Billion 0.01x 0.09x
2020 $4.38 Billion $566.78 Billion $104.68 Billion 0.01x 0.04x
2021 $4.95 Billion $630.60 Billion $139.63 Billion 0.01x 0.04x
2022 $4.33 Billion $802.75 Billion $155.58 Billion 0.01x 0.03x
2023 $4.81 Billion $805.16 Billion $158.85 Billion 0.01x 0.03x
2024 $5.32 Billion $857.54 Billion $239.24 Billion 0.01x 0.02x
2025 $5.54 Billion $928.96 Billion $232.34 Billion 0.01x 0.02x

Competitor Companies of RIG2 by Market Capitalization

Companies near Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt in the global market cap rankings as of June 18, 2026.

Key companies related to Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#513 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#561 GALDERMA GROUP AG NYSE:GALDY $48.78 Billion $43.22
#624 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $44.20 Billion CN¥47.35
#635 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €13.60

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Historical Marketcap From 2015 to 2026

Between 2015 and today, Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market cap moved from $3.70 Billion to $ 7.33 Billion, with a yearly change of 8.11%.

Year Market Cap Change (%)
2026 €7.33 Billion +32.33%
2025 €5.54 Billion +4.17%
2024 €5.32 Billion +10.55%
2023 €4.81 Billion +11.13%
2022 €4.33 Billion -12.58%
2021 €4.95 Billion +13.16%
2020 €4.38 Billion +8.00%
2019 €4.05 Billion +13.91%
2018 €3.56 Billion -22.63%
2017 €4.60 Billion +10.88%
2016 €4.15 Billion +11.98%
2015 €3.70 Billion --

End of Day Market Cap According to Different Sources

On Jun 17th, 2026 the market cap of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt was reported to be:

Source Market Cap
Yahoo Finance $6.56 Billion USD
MoneyControl $6.56 Billion USD
MarketWatch $6.56 Billion USD
marketcap.company $6.56 Billion USD
Reuters $6.56 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt

F:RIG2 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$7.33 Billion
€6.27 Billion EUR
Market Cap Rank
#3042 Global
#590 in Germany
Share Price
€34.38
Change (1 day)
+1.54%
52-Week Range
€24.60 - €36.66
All Time High
€36.66
About

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chron… Read more